Table 2.
Customizing adjuvant therapy trials
| References | Design | Biomakers tested | Results |
|---|---|---|---|
| Wislez et al22 | Phase II, multicentric | ERCC1, EGFR | ERCC1 IHC unreliable |
| Bepler et al19 | Phase II, multicentric | ERCC1, RRM1 | ERCC1 IHC unreliable |
| Gerber et al24 | Phase III, multicentric | ALK, EGFR | Ongoing |
| Novello et al25 | Phase II, multicentric | ERCC1, TS phenotype | Ongoing |
| Clinical trial26 | Phase III, multicentric | BRCA1 | Ongoing |
| Clinical trial27 | Phase III, multicentric | EGFR | Ongoing |
Abbreviations: ERCC1, excision repair cross-complementing 1; RRM1, ribonucleotide reductase M1; TS, thymidylate synthase; EGFR, epidermal growth factor receptor; ALK, anaplastic lymphoma kinase translocation; BRCA1, breast cancer 1 gene; IHC, immunohistochemical.